New Nordic fund prone for second investment – pours millions into antiviral spinout

In cooperation with the Danish Growth Fund, the recently launched life science fund Eir Ventures has invested a few million dollars into biotech firm Synklino, which is developing an antiviral medication with an annual revenue outlook of USD 1 billion.

Thomas N. Kledal (right), co-founder and CEO of Synklino; John Haurum (left), Synklino's chair. Photo: Synklino / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles